These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14708611)

  • 1. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells.
    Budiyanto A; Bito T; Kunisada M; Ashida M; Ichihashi M; Ueda M
    J Invest Dermatol; 2003 Nov; 121(5):1088-94. PubMed ID: 14708611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoic acid suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma.
    Kunisada M; Budiyanto A; Bito T; Nishigori C; Ueda M
    Br J Dermatol; 2005 Mar; 152(3):435-43. PubMed ID: 15787811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.
    McGregor F; Muntoni A; Fleming J; Brown J; Felix DH; MacDonald DG; Parkinson EK; Harrison PR
    Cancer Res; 2002 Aug; 62(16):4757-66. PubMed ID: 12183435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
    Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor.
    El-Abaseri TB; Fuhrman J; Trempus C; Shendrik I; Tennant RW; Hansen LA
    Cancer Res; 2005 May; 65(9):3958-65. PubMed ID: 15867397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells.
    Hsu CP; Lee LW; Tang SC; Hsin IL; Lin YW; Ko JL
    Tumour Biol; 2015 Jul; 36(7):5389-98. PubMed ID: 25680408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
    Gao Z; Chen W; Zhang X; Cai P; Fang X; Xu Q; Sun Y; Gu Y
    Biomed Pharmacother; 2013 Jun; 67(5):351-6. PubMed ID: 23602321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of apoptosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-10A cell line: correlation with increased transforming growth factor alpha production.
    Davis JW; Lauer FT; Burdick AD; Hudson LG; Burchiel SW
    Cancer Res; 2001 Apr; 61(8):3314-20. PubMed ID: 11309286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
    Benaud CM; Dickson RB
    Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.
    Bergström JD; Westermark B; Heldin NE
    Exp Cell Res; 2000 Aug; 259(1):293-9. PubMed ID: 10942601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
    Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P
    Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.